Snapshot from Aug 24, 2026 at 07:00 UTC. For live data and tracking: View Live
Regulatory legal inquiry

M&A Class Action Firm Investigates Mergers

Analysis based on 22 articles · First reported Jul 20, 2026 · Last updated Aug 06, 2026

Sentiment
-10
Attention
1
Articles
22
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard

The investigations may create uncertainty around the affected mergers, potentially influencing shareholder votes and deal completion. However, the impact is likely limited as these are routine legal inquiries by a class action firm, and the outcomes are uncertain.

Legal Services Financial Services

Monteverde & Associates PC, a securities class action firm, has launched and continued investigations into numerous proposed mergers and acquisitions on behalf of shareholders. The firm is examining the terms of transactions involving companies such as Crinetics Pharmaceuticals, Simulations Plus, NCS Multistage Holdings, Passage Bio, Dominion Energy, NextEra Energy, Arcosa, Selectis Health, Utz Brands, Neuphoria Therapeutics, National Insurance Company, Northrim Bancorp, PSB Holdings, Standard Biotools, Rallybio Corporation, Leggett & Platt, and LivePerson. The investigations focus on whether the boards of directors of the target companies fulfilled their fiduciary duties in approving the deals. The firm encourages shareholders to contact them for more information and to potentially join legal actions. The investigations are ongoing, with shareholder votes scheduled for various dates in August and September 2026.

100 Monteverde & Associates PC investigated mergers
priv
The law firm is the primary actor, conducting investigations into multiple mergers, which could lead to shareholder lawsuits and potential settlements.
Importance 100.0 Sentiment 0.0
per
As the attorney leading the investigations, his actions drive the legal inquiries and potential litigation.
Importance 80.0 Sentiment 0.0
stock
Target of investigation regarding its sale to NextEra; shareholders may receive 0.8138 NextEra shares per share.
Importance 60.0 Sentiment -10.0
stock
Target of investigation regarding its sale to Vertex Pharmaceuticals; shareholders may receive $85 per share, but the inquiry could affect the deal.
Importance 60.0 Sentiment -10.0
stock
Acquirer in the Dominion merger; shareholders will own 74.5% of combined company.
Importance 50.0 Sentiment -5.0
stock
Acquirer in the Crinetics deal; the investigation may scrutinize the transaction terms.
Importance 50.0 Sentiment -5.0
stock
Target of investigation regarding its sale to Altaris; shareholders may receive $18.50 per share.
Importance 50.0 Sentiment -10.0
stock
Target of investigation regarding its merger with Weatherford; shareholders may receive Weatherford stock.
Importance 50.0 Sentiment -10.0
stock
Target of investigation regarding its sale to CRH plc — CRH Americas; shareholders may receive $150 per share.
Importance 50.0 Sentiment -10.0
stock
Target of investigation regarding its sale to Intersnack; shareholders may receive $14.25 per share.
Importance 50.0 Sentiment -10.0
priv
Target of investigation regarding its sale to Mapfre; stockholders may receive $105 per share.
Importance 50.0 Sentiment -10.0
stock
Target of investigation regarding its sale to Somnigroup; shareholders will receive 0.1455 Somnigroup shares per share.
Importance 50.0 Sentiment -10.0
stock
Target of investigation regarding its sale to SoundHound AI for $43 million equity value.
Importance 50.0 Sentiment -10.0
priv
Acquirer in the Simulations Plus deal; subject to investigation.
Importance 40.0 Sentiment -5.0
stock
Acquirer in the NCS Multistage merger; subject to investigation.
Importance 40.0 Sentiment -5.0
+ 19 more entities View on Dashboard
Dominion Energy target NextEra Energy Dominion Energy is the target of a pending $66.8 billion all-stock acquisition by NextEra Energy. The transaction, annou
Crinetics Pharmaceuticals acquisition target Vertex Pharmaceuticals Crinetics Pharmaceuticals is the target of an acquisition by Vertex Pharmaceuticals, with the deal valued at approximate
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.